Vivos Therapeutics Net Income
| VVOS Stock | USD 1.37 0.07 4.86% |
As of the 5th of March, Vivos Therapeutics has the Variance of 22.78, coefficient of variation of (850.38), and Risk Adjusted Performance of (0.08). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Vivos Therapeutics, as well as the relationship between them. Please validate Vivos Therapeutics risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Vivos Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 1.37 per share. Given that Vivos Therapeutics is a hitting penny stock territory we recommend to closely look at its jensen alpha.
Vivos Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.3958 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -10 M | -10.5 M | |
| Net Loss | -18.3 M | -19.2 M | |
| Net Loss | -10 M | -10.5 M | |
| Net Loss | (2.00) | (2.10) | |
| Net Income Per E B T | 1.15 | 1.11 |
Vivos | Net Income | Build AI portfolio with Vivos Stock |
The evolution of Net Income for Vivos Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Vivos Therapeutics compares to historical norms and industry peers.
Latest Vivos Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Vivos Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Vivos Therapeutics financial statement analysis. It represents the amount of money remaining after all of Vivos Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Vivos Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vivos Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (11.14 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Vivos Net Income Regression Statistics
| Arithmetic Mean | (11,123,142) | |
| Coefficient Of Variation | (39.86) | |
| Mean Deviation | 2,976,270 | |
| Median | (8,542,130) | |
| Standard Deviation | 4,433,656 | |
| Sample Variance | 19.7T | |
| Range | 15.3M | |
| R-Value | (0.48) | |
| Mean Square Error | 16.1T | |
| R-Squared | 0.23 | |
| Significance | 0.05 | |
| Slope | (423,251) | |
| Total Sum of Squares | 314.5T |
Vivos Net Income History
Other Fundumenentals of Vivos Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Vivos Therapeutics Net Income component correlations
Vivos Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Vivos Therapeutics is extremely important. It helps to project a fair market value of Vivos Stock properly, considering its historical fundamentals such as Net Income. Since Vivos Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vivos Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vivos Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Equipment & Supplies market expansion? Will Vivos introduce new products? Factors like these will boost the valuation of Vivos Therapeutics. If investors know Vivos will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Vivos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share | Quarterly Revenue Growth 0.757 | Return On Assets | Return On Equity |
Investors evaluate Vivos Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Vivos Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Vivos Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Vivos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vivos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Vivos Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Vivos Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Vivos Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Vivos Therapeutics.
| 12/05/2025 |
| 03/05/2026 |
If you would invest 0.00 in Vivos Therapeutics on December 5, 2025 and sell it all today you would earn a total of 0.00 from holding Vivos Therapeutics or generate 0.0% return on investment in Vivos Therapeutics over 90 days. Vivos Therapeutics is related to or competes with Allurion Technologies, EnVVeno Medical, Co Diagnostics, Aethlon Medical, Envoy Medical, Adagio Medical, and OSR Holdings. Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients ... More
Vivos Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Vivos Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Vivos Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.13) | |||
| Maximum Drawdown | 31.84 | |||
| Value At Risk | (6.75) | |||
| Potential Upside | 6.67 |
Vivos Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vivos Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Vivos Therapeutics' standard deviation. In reality, there are many statistical measures that can use Vivos Therapeutics historical prices to predict the future Vivos Therapeutics' volatility.| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.38) |
Vivos Therapeutics March 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.37) | |||
| Mean Deviation | 3.24 | |||
| Coefficient Of Variation | (850.38) | |||
| Standard Deviation | 4.77 | |||
| Variance | 22.78 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.62) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.38) | |||
| Maximum Drawdown | 31.84 | |||
| Value At Risk | (6.75) | |||
| Potential Upside | 6.67 | |||
| Skewness | 2.37 | |||
| Kurtosis | 10.94 |
Vivos Therapeutics Backtested Returns
Vivos Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.1, which indicates the firm had a -0.1 % return per unit of risk over the last 3 months. Vivos Therapeutics exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Vivos Therapeutics' Risk Adjusted Performance of (0.08), coefficient of variation of (850.38), and Variance of 22.78 to confirm the risk estimate we provide. The entity has a beta of 1.5, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vivos Therapeutics will likely underperform. At this point, Vivos Therapeutics has a negative expected return of -0.49%. Please make sure to validate Vivos Therapeutics' information ratio, as well as the relationship between the kurtosis and relative strength index , to decide if Vivos Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.08 |
Virtually no predictability
Vivos Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Vivos Therapeutics time series from 5th of December 2025 to 19th of January 2026 and 19th of January 2026 to 5th of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vivos Therapeutics price movement. The serial correlation of 0.08 indicates that barely 8.0% of current Vivos Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.08 | |
| Spearman Rank Test | 0.15 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Vivos Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Vivos Therapeutics reported net income of (11.14 Million). This is 103.26% lower than that of the Health Care Equipment & Supplies sector and 104.68% lower than that of the Health Care industry. The net income for all United States stocks is 101.95% higher than that of the company.
Vivos Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vivos Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vivos Therapeutics could also be used in its relative valuation, which is a method of valuing Vivos Therapeutics by comparing valuation metrics of similar companies.Vivos Therapeutics is currently under evaluation in net income category among its peers.
Vivos Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Vivos Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Vivos Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vivos Therapeutics' value.| Shares | Advisor Group Holdings, Inc. | 2025-09-30 | 6.6 K | Tower Research Capital Llc | 2025-09-30 | 2.8 K | Morgan Stanley - Brokerage Accounts | 2025-09-30 | 1.1 K | Signaturefd, Llc | 2025-09-30 | 547 | Ronald Blue Trust, Inc. | 2025-12-31 | 160 | Bank Of America Corp | 2025-09-30 | 117 | Ubs Group Ag | 2025-09-30 | 102 | Kozak & Associates, Inc. | 2025-09-30 | 49.0 | Global Retirement Partners, Llc. | 2025-09-30 | 23.0 | Vanguard Group Inc | 2025-12-31 | 304.2 K | Connective Capital Management Llc | 2025-09-30 | 200 K |
Vivos Fundamentals
| Return On Equity | -3.35 | ||||
| Return On Asset | -0.5 | ||||
| Profit Margin | (0.99) % | ||||
| Operating Margin | (0.70) % | ||||
| Current Valuation | 24.17 M | ||||
| Shares Outstanding | 10.47 M | ||||
| Shares Owned By Insiders | 23.48 % | ||||
| Shares Owned By Institutions | 11.03 % | ||||
| Number Of Shares Shorted | 465.16 K | ||||
| Price To Book | 5.83 X | ||||
| Price To Sales | 0.89 X | ||||
| Revenue | 15.03 M | ||||
| Gross Profit | 9.65 M | ||||
| EBITDA | (10.55 M) | ||||
| Net Income | (11.14 M) | ||||
| Cash And Equivalents | 17.83 M | ||||
| Cash Per Share | 0.77 X | ||||
| Total Debt | 1.51 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 3.15 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (12.69 M) | ||||
| Short Ratio | 3.35 X | ||||
| Earnings Per Share | (1.77) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 262 | ||||
| Beta | 7.02 | ||||
| Market Capitalization | 15.42 M | ||||
| Total Asset | 15.28 M | ||||
| Retained Earnings | (104.19 M) | ||||
| Working Capital | 2.5 M | ||||
| Net Asset | 15.28 M |
About Vivos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vivos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vivos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vivos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.